natgillin/translations-raw huggingface dataset:
Patients should be closely monitored for tenofovir disoproxil fumarate-associated adverse reactions, including renal disorders. 
Bolesnike treba pažljivo nadzirati zbog nuspojava tenofovirdizoproksilfumarata, uključujući poremećaje bubrega.
Table 8: Steady-State Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Pregnant Women in the Fed State atazanavir 300 mg with ritonavir 100 mg 
Tablica 8: Farmakokinetika atazanavira s ritonavirom u stanju dinamičke ravnoteže u trudnica zaraženih HIV-om u sitom stanju atazanavir 300 mg s ritonavirom 100 mg
• gynaecomastia (breast enlargement in men) 
• ginekomastija (povećanje grudi u muškaraca)
If you notice any of these symptoms please inform your doctor. 
Ako primijetite neki od ovih simptoma, obavijestite o tome svog liječnika.
Atazanavir plasma trough concentrations were approximately 2-fold higher during the postpartum period when compared to those observed historically in HIV infected non-pregnant patients. 
Najniže koncentracije atazanavira u plazmi bile su približno dvostruko više tijekom postpartalnog razdoblja u usporedbi s onima prethodno opaženima u bolesnica zaraženih HIV-om koje nisu bile trudne.
Rifabutin 150 mg twice weekly 
Rifabutin 150 mg dvaput tjedno
- The other ingredients are lactose monohydrate, crospovidone, magnesium stearate. 
Drugi su sastojci laktoza hidrat, krospovidon, magnezijev stearat.
Atazanavir (without ritonavir) has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily. 
Atazanavir (bez ritonavira) ispitan je u odraslih bolesnika s teškim oštećenjem funkcije bubrega (n=20), uključujući one na hemodijalizi, pomoću višestrukih doza od 400 mg jedanput na dan.
What Atazanavir Mylan looks like and contents of the pack 
Kako Atazanavir Mylan izgleda i sadržaj pakiranja
Eleven subjects (13%) in the unboosted atazanavir group and 6 (7%) in the atazanavir + ritonavir group, had virologic rebound. 
U jedanaest ispitanika (13%) u skupini liječenoj nepojačanim atazanavirom i 6 (7%) ispitanika u skupini koja je primala atazanavir + ritonavir virusno je opterećenje ponovno postalo mjerljivo.
If you develop a rash inform your doctor immediately. 
Ako razvijete osip, odmah o tome obavijestite svog liječnika.
The risk of myopathy including rhabdomyolysis may also be increased with atorvastatin, which is also metabolised by CYP3A4. 
Rizik od miopatije, uključujući rabdomiolizu, također može biti povećan s primjenom atorvastatina, koji također metabolizira enzim CYP3A4.
This decrease in atazanavir exposure might negatively impact the efficacy of atazanavir. 
Ovo smanjenje izloženosti atazanaviru može negativno utjecati na djelotvornost atazanavira.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products (see section 4.8). 
U slučaju istovremene antivirusne terapije zbog hepatitisa B ili C treba provjeriti odgovarajuće Sažetke opisa svojstava lijeka za te lijekove (vidjeti dio
Regular monitoring of the renal function of patients should be maintained throughout the treatment duration (see section 4.4). 
Redovito praćenje bubrežnih funkcija u bolesnika treba se održavati tijekom cijelog trajanja liječenja (pogledajte dio 4.4).
2nd Trimester (n=9) 
2. tromjesečje (n=9)
The most frequently reported laboratory abnormality in patients receiving regimens containing atazanavir and one or more NRTIs was elevated total bilirubin reported predominantly as elevated indirect [unconjugated] bilirubin (87% Grade 1, 2, 3, or 4). 
Najčešće zabilježeni laboratorijski nalaz u bolesnika koji primaju terapiju atazanavirom i jednim ili više NRTI-jeva bio je povišen ukupni bilirubin zabilježen pretežno kao povišeni indirektni [nekonjugirani] bilirubin (87% 1., 2., 3. ili 4. stupnja).
Ethinyloestradiol 35 µg + norethindrone 
Etinilestradiol 35 μg + noretindron
The dose of Atazanavir Mylan capsules for children is calculated by body weight and is taken once daily with food and 100 mg ritonavir as shown below: 
Doza Atazanavir Mylan kapsula za djecu izračunava se na temelju tjelesne težine i uzima se jedanput na dan s hranom i 100 mg ritonavira na sljedeći način:
Clarithromycin Cmax ↑50% (↑32% 
Klaritromicin Cmax ↑50% (↑32%
Co-administration of atazanavir with ritonavir at doses greater than 100 mg once daily has not been clinically evaluated. 
Istovremena primjena atazanavira s ritonavirom u dozama višima od 100 mg jedanput na dan nije klinički procijenjena.
• if you are taking any of these medicines: see also Other medicines and Atazanavir Mylan - rifampicin, an antibiotic used to treat tuberculosis - astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); quinidine or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland). 
• ako uzimate neki od ovih lijekova: vidjeti također Drugi lijekovi i Atazanavir Mylan - rifampicin, antibiotik za liječenje tuberkuloze - astemizol ili terfenadin (obično se primjenjuju za liječenje simptoma alergije i mogu se nabaviti bez recepta); cisaprid (primjenjuje se za liječenje želučanog refluksa, tj. žgaravice); pimozid (primjenjuje se za liječenje shizofrenije); kinidin ili bepridil (primjenjuju se za liječenje poremećaja srčanog ritma); ergotamin, dihidroergotamin, ergonovin, metilergonovin (primjenjuju se za liječenje glavobolje); i alfuzosin (primjenjuje se za liječenje povećanja prostate)
Of importance, many studies were conducted with unboosted atazanavir, which is not the recommended regimen of atazanavir (see section 4.4). 
Važno je istaknuti da su mnoga ispitivanja provedena s nepojačanim atazanavirom, što nije preporučen oblik liječenja atazanavirom (vidjeti dio 4.4).
Age/gender 
Dob/Spol
Contains lactose See leaflet for further information. 
Sadrži laktozu Vidjeti uputu o lijeku za dodatne informacije.
Therefore, postpartum patients should be closely monitored for adverse reactions. 
Stoga, bolesnice u postpartalnom razdoblju treba pažljivo pratiti zbog nuspojava.
Subjects without a functional CYP2C19 allele. 
Osobe bez funkcionalnog CYP2C19 alela.
The absorption of atazanavir may be reduced in situations where gastric pH is increased irrespective of cause. 
Apsorpcija atazanavira može biti smanjena kad je povišen želučani pH, bez obzira na uzrok.
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. 
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja kombinirane antiretrovirusne terapije (CART) može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, što može prouzročiti ozbiljno kliničko stanje ili pogoršanje simptoma.
There were no cases of lactic acidosis observed in the clinical trial AI424-182. 
U kliničkom ispitivanju AI424-182 nije opažen niti jedan slučaj laktacidoze.
In case of withdrawal of ritonavir from the initial recommended ritonavir boosted regimen (see section 4.4), unboosted atazanavir could be maintained in patients with mild hepatic impairment at a dose of 400 mg and in patients with moderate hepatic impairment with a reduced dose of 300 mg once daily with food (see section 5.2). 
U slučaju izostavljanja ritonavira iz početnog preporučenog režima pojačanog ritonavirom (vidjeti dio 4.4), nepojačani atazanavir može se nastaviti primjenjivati u bolesnika s blagim oštećenjem jetre u dozi od 400 mg, a u bolesnika s umjerenim oštećenjem funkcije jetre doza se mora smanjiti na 300 mg jedanput na dan i uzimati s hranom (vidjeti dio 5.2).
C-atazanavir, 79% and 13% of the total radioactivity was recovered in the faeces and urine, respectively. 
C-atazanavira, 79% ukupne radioaktivnosti otkriveno je u stolici, a 13% u mokraći.
When atazanavir/ritonavir is co-administered with either phenytoin or phenobarbital, a dose adjustment of phenytoin or phenobarbital may be required. 
Kada se atazanavir s ritonavirom primjenjuje istodobno s fenitoinom ili fenobarbitalom, možda će biti potrebna prilagodba doze fenitoina ili fenobarbitala.
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. 
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme početka kombinirane antiretrovirusne terapije (CART) može nastupiti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
Particular caution should be used when prescribing Atazanavir Mylan in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3). 
Osobit se oprez treba primijeniti kad se Atazanavir Mylan propisuje zajedno s drugim lijekovima koji mogu produljiti QT interval i/ili u bolesnika s već prisutnim čimbenicima rizika (bradikardija, kongenitalno produljeni QT interval, poremećaji elektrolita) (vidjeti dijelove 4.8 i 5.3).
Select substitutions include any change at positions L10, K20, L24, V32, L33, M36, M46, G48, I50, I54, L63, A71, G73, V82, I84, and L90 (0-2, 3, 4 or more) at baseline. 
Odabrane supstitucije uključuju svaku promjenu na položajima: L10, K20, L24, V32, L33, M36, M46, G48, I50, I54, L63, A71, G73, V82, I84 i L90 (0-2, 3, 4 ili više) na početku.
common: headache; uncommon: peripheral neuropathy, syncope, amnesia, dizziness, somnolence, dysgeusia 
često: glavobolja; manje često: periferna neuropatija, sinkopa, amnezija, omaglica, somnolencija, disgeuzija
Atazanavir exhibits anti- HIV-1 (including all clades tested) and anti-HIV-2 activity in cell culture. 
Atazanavir u staničnoj kulturi ima anti-HIV-1 (uključujući sve ispitane skupine) i anti-HIV-2 djelovanje.
Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with atazanavir. 
Osipi su obično blage do umjerene makulopapularne erupcije koje nastaju tijekom prva 3 tjedna od početka terapije atazanavirom.
In a nonclinical fertility and early embryonic development study in rats, atazanavir altered oestrus cycling with no effects on mating or fertility (see section 5.3). 
U nekliničkim ispitivanjima utjecaja na plodnost i rani embrionalni razvoj u štakora, atazanavir je promijenio ciklus estrusa bez učinaka na parenje ili plodnost (vidjeti dio 5.3).
Co-administration of atazanavir/ritonavir with boceprevir resulted in lower exposure of atazanavir which may be associated with lower efficacy and loss of HIV control. 
Istovremena primjena kombinacije atazanavir/ritonavir s boceprevirom rezultirala je manjom izloženošću atazanaviru, što može biti povezano s manjom djelotvornošću i gubitkom kontrole HIV-a.
• interstitial nephritis (kidney inflammation), haematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination) 
• intersticijalni nefritis (upala bubrega), hematurija (krv u mokraći), proteinurija (višak proteina u mokraći), polakizurija (učestalo mokrenje)
Clarithromycin AUC ↑94% (↑75% 
Klaritromicin AUC ↑94% (↑75%
ANTIPSYCHOTICS Quetiapine 
ANTIPSIHOTICI Kvetiapin
The choice of Atazanavir Mylan in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history (see sections 4.4 and 5.1). 
Odabir lijeka Atazanavir Mylan u prethodno liječenih odraslih i pedijatrijskih bolesnika treba biti utemeljen na pojedinačnom testiranju virusne rezistencije i prethodnom liječenju pojedinog bolesnika (vidjeti dijelove 4.4 i 5.1).
Other side effects reported for patients treated with atazanavir are the following: 
Druge nuspojave prijavljene u bolesnika liječenih atazanavirom:
HORMONAL CONTRACEPTIVES Ethinyloestradiol 25 μg + norgestimate 
Etinilestradiol 25 μg + norgestimat
Atazanavir has been evaluated for safety in combination therapy with other antiretroviral medicinal products in controlled clinical trials in 1,806 adult patients receiving atazanavir 400 mg once daily (1,151 patients, 52 weeks median duration and 152 weeks maximum duration) or atazanavir 300 mg with ritonavir 100 mg once daily (655 patients, 96°weeks median duration and 108 weeks maximum duration). 
Sigurnost atazanavira procijenjena je u kombiniranoj terapiji s drugim antiretrovirusnim lijekovima u kontroliranim kliničkim ispitivanjima u 1806 odraslih bolesnika koji su primali atazanavir 400 mg jedanput na dan (1151 bolesnika, medijan trajanja liječenja 52 tjedna i maksimalno trajanje liječenja 152 tjedna) ili atazanavir 300 mg s ritonavirom 100 mg jedanput na dan (655 bolesnika, medijan trajanja liječenja 96 tjedana i maksimalno trajanje liječenja 108 tjedana).
Atazanavir (am): 2 hr after omeprazole 
Atazanavir (am): 2 sata nakon omeprazola
100 to <200 cells/mm 
100 do <200 stanica /mm
For co-administration of sildenafil for the treatment of erectile dysfunction see sections 4.4 and 4.5. 
Za istovremenu primjenu sildenafila zbog liječenja erektilne disfunkcije, vidjeti dijelove 4.4 i 4.5.
Consistent results were obtained with the last observation carried forward method of analysis. 
Metodom analize u kojoj se koristi prijenos posljednjih zabilježenih rezultata dobiveni su dosljedni rezultati.
In the majority of patients, a reduction in both voriconazole and atazanavir exposures are expected. 
U većine bolesnika očekuje se smanjena izloženost kako vorikonazolu tako i atazanaviru.
Atazanavir Cmin ↓20% (↓31% ↓8%) In Healthy volunteers with atazanavir/ritonavir at an increased dose of 400/100 mg once daily 
Atazanavir Cmin ↓20% (↓31% ↓8%) Primjena atazanavira/ritonavira u povišenoj dozi od 400/100 mg jedanput na dan u zdravih dobrovoljaca
There is no specific antidote for overdose with atazanavir. 
Ne postoji posebni antidot za predoziranje atazanavirom.
uncommon: torsades de pointes a rare: QTc prolongation a, oedema, palpitation 
manje često: torsades de pointes a rijetko: produljenje QTc intervala a, edem, palpitacije
In clinical trials of antiretroviral treatment naive patients treated with unboosted atazanavir, the I50L substitution, sometimes in combination with an A71V change, is the signature resistance substitution for atazanavir. 
U kliničkim ispitivanjima antiretrovirusnog liječenja nepojačanim atazanavirom u bolesnika koji prethodno nisu bili liječeni, supstitucija I50L, ponekad u kombinaciji s promjenom na A71V, tipična je za rezistenciju na atazanavir.
Atazanavir (am): 1 hr after omeprazole 
Atazanavir (am): 1 sat nakon omeprazola
Co-administration of atazanavir /ritonavir with other hormonal contraceptives or oral contraceptives containing progestogens other than norgestimate has not been studied, and therefore should be avoided. 
Istovremena primjena atazanavira s ritonavirom i druge hormonske ili oralne kontracepcije koja sadrži progestagene, osim norgestimata, nije ispitana i stoga je treba izbjegavati.
Diltiazem 180 mg once daily 
Diltiazem 180 mg jedanput na dan
The atazanavir/ritonavir arm showed similar (non-inferior) antiviral efficacy compared to the lopinavir/ritonavir arm, as assessed by the proportion of patients with HIV RNA < 50 copies/ml at week 48 (Table 5). 
U skupini koja je primala atazanavir/ritonavir utvrđena je antivirusna djelotvornost slična (neinferiorna) onoj u skupini koja je primala lopinavir/ritonavir, što je procijenjeno na temelju udjela bolesnika s HIV RNK < 50 kopija/ml u 48. tjednu (tablica 5).
Atazanavir may affect how well your kidneys work. 
Atazanavir može utjecati na to kako dobro rade vaši bubrezi.
Due to carbamazepine inducing effect, a reduction in atazanavir exposure cannot be ruled out. 
Zbog inducirajućeg učinka karbamazepina, ne može se isključiti smanjena izloženost atazanaviru.
For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. 
Za nadzor lipida i glukoze u krvi date su preporuke u su u utvrđenim smjernicama za liječenje HIV-a.
Atazanavir has been detected in human milk. 
Atazanavir je pronađen u majčinom mlijeku.
The studies presented in Table 2 were conducted in healthy subjects unless otherwise noted. 
Ako nije drugačije naznačeno, ispitivanja prikazana u tablici 2 provedena su u zdravih ispitanika.
Week 48 Week 96 Week 48 Week 96 Week 48 Week 96 HIV RNA Mean Change from Baseline, log10 copies/ml All patients 
d] 48. tjedan 96. tjedan 48. tjedan 96. tjedan 48. tjedan 96. tjedan HIV RNK prosječna promjena u odnosu na početnu vrijednost, log10 kopija/ml
Atazanavir (without ritonavir) has been studied in adult subjects with moderate-to-severe hepatic impairment (14 Child-Pugh Class B and 2 ChildPugh Class C subjects) after a single 400 mg dose. 
Atazanavir (bez ritonavira) ispitivao se u odraslih ispitanika s umjerenim do teškim oštećenjem funkcije jetre (14 ispitanika s Child-Pugh stadijem B i 2 ispitanika s Child-Pugh stadijem C) nakon primjene jednokratne doze od 400 mg.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg once daily 
Nenukleozidni inhibitori reverzne transkriptaze (NNRTI-jevi) Efavirenz 600 mg jedanput na dan
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occurs many months after initiation of treatment. 
Autoimune bolesti (kao što je Gravesova bolest i autoimunog hepatitisa) su također bile prijavljene; međutim, vrijeme prijave pojave tih bolesti je vrlo varijabilno jer se mogu dogoditi i više mjeseci nakon početka liječenja. (vidjeti dio 4.4).
PI major L24I, D30N, V32I, L33F, M46IL, I47AV, G48V, I50LV, F53LY,I54ALMSTV, L76V, V82AFLST, I84V, N88DS, L90M; PI minor: L10CFIRV, V11I, E35G, K43T, Q58E, A71ILTV, G73ACST, T74P, N83D, L89V. 
Glavna supstitucija za rezistenciju na inhibitore proteaze L24I, D30N, V32I, L33F, M46IL, I47AV, G48V, I50LV, F53LY,I54ALMSTV, L76V, V82AFLST, I84V, N88DS, L90M; sporedna supstitucija za rezistenciju na inhibitore proteaze: L10CFIRV, V11I, E35G, K43T, Q58E, A71ILTV, G73ACST, T74P, N83D, L89V.
If signs or symptoms of nephrolithiasis occur, temporary interruption or discontinuation of treatment may be considered. 
Ako se pojave znakovi i simptomi nefrolitijaze, može se razmotriti privremeni ili trajni prekid liječenja.
A dose equivalent to famotidine 40 mg twice daily should not be exceeded. 
Ne smije se prekoračiti doza jednaka dozi famotidina od 40 mg dvaput na dan.
Ketoconazole and itraconazole should be used cautiously with atazanavir/ritonavir. 
Ketokonazol i itrakonazol treba primjenjivati s oprezom kad se daju s atazanavirom/ritonavirom.
Co-administration with atazanavir with ritonavir warrants clinical monitoring for sedation and cognitive effects. 
Istovremena primjena s atazanavirom i ritonavirom zahtijeva kliničko praćenje zbog sedacije i kognitivnih učinaka.
Other medicines and Atazanavir Mylan 
Drugi lijekovi i Atazanavir Mylan
Irinotecan 
Irinotekan
ANTINEOPLASTICS AND IMMUNOSUPRESSANTS Antineoplastics 
ANTINEOPLASTICI I IMUNOSUPRESIVI
• atorvastatin, pravastatin, and fluvastatin (used to lower blood cholesterol) 
• atorvastatin, pravastatin i fluvastatin (primjenjuju se za snižavanje kolesterola u krvi)
Among patients receiving atazanavir 300 mg with ritonavir 100 mg, the frequency of jaundice was 19%. 
Među bolesnicima koji su primali atazanavir 300 mg s ritonavirom 100 mg, učestalost žutice bila je 19%.
Co-administration of atazanavir and ritonavir with food optimises the bioavailability of atazanavir. 
Istovremena primjena atazanavira i ritonavira s hranom optimizira bioraspoloživost atazanavira.
• viral strains not harbouring HIV resistance-associated mutations (RAMs) to current regimen. 
• virusni sojevi koji nisu nositelji mutacija povezanih s rezistencijom HIV-a na trenutni režim liječenja.
Systemic exposures of atazanavir in mice (males), rats, and dogs at doses associated with hepatic changes were at least equal to that observed in humans given 400 mg once daily. 
Sistemska izloženost miševa (mužjaka), štakora i pasa atazanaviru primijenjenom u dozama koje su povezane s jetrenim promjenama bila je barem jednaka onoj opaženoj u ljudi koji su dobivali 400 mg jedanput na dan.
The increase in progestin exposure may lead to related side-effects (e.g. insulin resistance, dyslipidemia, acne and spotting), thus possibly affecting the compliance. 
Povećana izloženost progestinu može dovesti do s time povezanih nuspojava (npr. inzulinske rezistencije, dislipidemije, akni i probojnog krvarenja) i tako utjecati na uzimanje kontracepcije.
In some cases, nephrolithiasis has been associated with acute renal failure or renal insufficiency. 
U nekim slučajevima, nefrolitijaza je povezana s akutnim zatajenjem bubrega ili bubrežnom insuficijencijom.
• grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection). 
• lijekovi koji sadrže grazoprevir, uključujući fiksnu kombinaciju elbasvira/grazoprevira (koja se koristi u liječenju kronične infekcije virusom hepatitisa C).
≥ 200 cells/mm 
≥ 200 stanica /mm
common: vomiting, diarrhoea, abdominal pain, nausea, dyspepsia; uncommon: pancreatitis, gastritis, abdominal distension, stomatitis aphthous, flatulence, dry mouth 
često: povraćanje, proljev, bol u abdomenu, mučnina, dispepsija; manje često: pankreatitis, gastritis, distenzija abdomena, aftozni stomatitis, flatulencija, suha usta
14-OH clarithromycin AUC ↓70% 
14-OH klaritromicin AUC ↓70%
Only when atazanavir with ritonavir is co-administered with efavirenz, a dose increase of ritonavir to 200 mg once daily could be considered. 
Samo kad se atazanavir s ritonavirom primjenjuje istovremeno s efavirenzom može se razmotriti povišenje doze ritonavira na 200 mg jedanput na dan.
Two percent of patients treated with atazanavir experienced concurrent Grade 3-4 ALT/AST and Grade 3-4 total bilirubin elevations. 
Dva posto bolesnika liječenih atazanavirom imalo je istovremeno ALT/AST 3.-4. stupnja i povišenje ukupnog bilirubina 3.-4. stupnja.
No dosage adjustments are needed for fluconazole and atazanavir. 
Nisu potrebne prilagodbe doze flukonazola i atazanavira.
uncommon: muscle atrophy, arthralgia, myalgia; rare: myopathy 
manje često: mišićna atrofija, artralgija, mialgija; rijetko: miopatija
Patients should not breast-feed while taking Atazanavir Mylan. 
Bolesnice ne smiju dojiti dok uzimaju Atazanavir Mylan.
Itraconazole 
Itrakonazol
If a higher dose of an H2-receptor antagonist is required (e.g., famotidine 40 mg twice daily or equivalent) an increase of the atazanavir/ritonavir dose from 300/100 mg to 400/100 mg can be considered. 
Ako je potrebna viša doza antagonista H2 receptora (npr., famotidin 40 mg dvaput na dan ili ekvivalent) može se razmotriti povišenje doze lijeka atazanavir s ritonavirom s 300/100 mg na 400/100 mg.
Atazanavir Mylan, co-administered with low dose ritonavir, is indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2). 
Atazanavir Mylan, primijenjen istovremeno s niskom dozom ritonavira, indiciran je u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih i pedijatrijskih bolesnika u dobi od 6 godina i starijih, koji su zaraženi virusom HIV 1 (vidjeti dio 4.2).
Unchanged drug accounted for approximately 20% and 7% of the administered dose in the faeces and urine, respectively. 
Neizmijenjeni lijek činio je približno 20% primijenjene doze u stolici, a 7% u mokraći.